Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Hirofumi Yamamoto, Ryota Oshiro, Junichi Nishimura, Mamoru Uemura, Naotsugu Haraguchi, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m 2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

Original languageEnglish
Pages (from-to)1751-1755
Number of pages5
JournalOncology reports
Volume29
Issue number5
DOIs
Publication statusPublished - May 1 2013
Externally publishedYes

Fingerprint

Aggressive Fibromatosis
Dacarbazine
Doxorubicin
Neoplasms
Therapeutics
Sulindac
Adenomatous Polyposis Coli
Muscular Diseases
Tamoxifen
Pelvis
Myocardium

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamamoto, H., Oshiro, R., Nishimura, J., Uemura, M., Haraguchi, N., Hata, T., ... Mori, M. (2013). Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. Oncology reports, 29(5), 1751-1755. https://doi.org/10.3892/or.2013.2345

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. / Yamamoto, Hirofumi; Oshiro, Ryota; Nishimura, Junichi; Uemura, Mamoru; Haraguchi, Naotsugu; Hata, Taishi; Takemasa, Ichiro; Mizushima, Tsunekazu; Sekimoto, Mitsugu; Doki, Yuichiro; Mori, Masaki.

In: Oncology reports, Vol. 29, No. 5, 01.05.2013, p. 1751-1755.

Research output: Contribution to journalArticle

Yamamoto, H, Oshiro, R, Nishimura, J, Uemura, M, Haraguchi, N, Hata, T, Takemasa, I, Mizushima, T, Sekimoto, M, Doki, Y & Mori, M 2013, 'Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors', Oncology reports, vol. 29, no. 5, pp. 1751-1755. https://doi.org/10.3892/or.2013.2345
Yamamoto H, Oshiro R, Nishimura J, Uemura M, Haraguchi N, Hata T et al. Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. Oncology reports. 2013 May 1;29(5):1751-1755. https://doi.org/10.3892/or.2013.2345
Yamamoto, Hirofumi ; Oshiro, Ryota ; Nishimura, Junichi ; Uemura, Mamoru ; Haraguchi, Naotsugu ; Hata, Taishi ; Takemasa, Ichiro ; Mizushima, Tsunekazu ; Sekimoto, Mitsugu ; Doki, Yuichiro ; Mori, Masaki. / Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. In: Oncology reports. 2013 ; Vol. 29, No. 5. pp. 1751-1755.
@article{bab78dc73d47467ba38c123954f3685d,
title = "Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors",
abstract = "Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m 2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.",
author = "Hirofumi Yamamoto and Ryota Oshiro and Junichi Nishimura and Mamoru Uemura and Naotsugu Haraguchi and Taishi Hata and Ichiro Takemasa and Tsunekazu Mizushima and Mitsugu Sekimoto and Yuichiro Doki and Masaki Mori",
year = "2013",
month = "5",
day = "1",
doi = "10.3892/or.2013.2345",
language = "English",
volume = "29",
pages = "1751--1755",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

AU - Yamamoto, Hirofumi

AU - Oshiro, Ryota

AU - Nishimura, Junichi

AU - Uemura, Mamoru

AU - Haraguchi, Naotsugu

AU - Hata, Taishi

AU - Takemasa, Ichiro

AU - Mizushima, Tsunekazu

AU - Sekimoto, Mitsugu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m 2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

AB - Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m 2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84876257549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876257549&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2345

DO - 10.3892/or.2013.2345

M3 - Article

C2 - 23503528

AN - SCOPUS:84876257549

VL - 29

SP - 1751

EP - 1755

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -